For the quarter ending 2026-03-31, PLX made $33,750K in revenue. $18,317K in net income. Net profit margin of 54.27%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenue | 33,750 | 2,481* | 17,851 | 15,658 |
| Cost of revenues | 4,127 | 5,701* | 8,324 | 5,870 |
| Research and development expenses | 5,426 | 3,881* | 4,467 | 5,992 |
| Selling, general, and administrative expenses | 3,051 | 3,353* | 2,929 | 2,624 |
| Operating income (loss) | 21,146 | -10,453* | 2,131 | 1,172 |
| Financial expenses | 193 | -254* | 180 | 783 |
| Financial income | 188 | 243* | 288 | 272 |
| Financial income (expenses), net | -5 | 497* | 108 | -511 |
| Income (loss) before taxes on income | 21,141 | -9,957* | 2,239 | 661 |
| Taxes on income (tax benefit) | 2,824 | 425* | -116 | 497 |
| Net income (loss) | 18,317 | -10,382 | 2,355 | 164 |
| Basic EPS | 0.23 | -0.134 | 0.03 | 0 |
| Diluted EPS | 0.22 | -0.141 | 0.03 | 0 |
| Basic Average Shares | 79,848,892 | 77,693,133 | 79,281,685 | 78,663,884 |
| Diluted Average Shares | 83,048,596 | 73,552,528 | 80,814,564 | 81,271,610 |
Protalix BioTherapeutics, Inc. (PLX)
Protalix BioTherapeutics, Inc. (PLX)